Immune-related ocular toxicities of PD-1/PD-L1 antibody versus chemotherapy for solid tumor: a meta-analysis

HOU Yanli; WANG Yanling; SU Qiang; HU Jiexuan; SONG Jie

PDF(771 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2020, Vol. 31 ›› Issue (8) : 661-664.

ORIGINAL ARTICLES

Immune-related ocular toxicities of PD-1/PD-L1 antibody versus chemotherapy for solid tumor: a meta-analysis

HOU Yanli¹, WANG Yanling¹, SU Qiang², HU Jiexuan², SONG Jie³

Author information +

History +

Abstract

Objective To evaluate the immune-related ocular toxicities of PD-1/PD-L1 antibody versus chemotherapy in patients with solid tumors.Methods Such databases as PubMed and EMbase were searched as of December 2019. Related phase Ⅱ-Ⅳ controlled clinical trials were included. The ocular toxicities caused by PD-1/PD-L1 antibody and by chemotherapy were compared in solid tumor patients. Meta-analysis was performed using RevMan 5.3.Results There was no statistically significant difference in the risk of grade 1-5 and grade 3-5 adverse events between PD-1/PD-L1 antibody and chemotherapy[OR=1.34,95%CI(0.64-2.80);OR=1.20,95%CI(0.35-4.08)].The cases were the same with PD-1antibody[OR=1.20,95%CI(0.55-2.65);OR=1.00,95%CI(0.26-3.86)] and PD-L1 antibody [OR=2.82,95%CI(0.29-27.19);OR=2.85,95%CI(0.12-70.15)].Conclusions Our meta-analysis demonstrates that there is no significant difference in immune-related ocular toxicities between PD-1/PD-L1 antibody and chemotherapy.

Key words

PD-1 antibody / PD-L antibody / chemotherapy / ocular toxicities / meta-analysis

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

HOU Yanli, WANG Yanling, SU Qiang, HU Jiexuan, SONG Jie. Immune-related ocular toxicities of PD-1/PD-L1 antibody versus chemotherapy for solid tumor: a meta-analysis[J]. Medical Journal of the Chinese People Armed Police Forces. 2020, 31(8): 661-664

References

[1] 张勇,白莉.免疫检查点治疗疗效预测因素研究进展[J].武警医学,2018, 29(5):523-528.
[2] Su Q, Zhu E C, Wu J B, et al. Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis[J]. Front Immunol,2019,10:108.
[3] Su Q, Zhang X C, Zhang C G, et al. Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis[J]. J Immunol Res,2018(2018):1-9.
[4] Su Q, Zhang X C, Wang D Y, et al. The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: a systematic review and meta-analysis[J].Int Immunopharmacol, 2018,59:328-338.
[5] Su Q, Zhang X, Shen X, et al.Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment[J].J Cancer,2018,9(9):1614-1622.
[6] Xu M, Nie Y, Yang Y, et al.Risk of neurological toxicities following the use of different immune checkpoint inhibitor regimens in solid tumors: a systematic review and meta-analysis[J]. Neurologist, 2019,24(3):75-83.
[7] Rittmeyer A, Barlesi F, Waterkamp D, et al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet,2016,389(10077):1837-1846.
[8] Barlesi F, Vansteenkiste J, Spigel D, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study[J].Lancet Oncol, 2018,19(11):1468-1479.
[9] Weber J S, D’Angelo S P, Minor D, et al.Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial[J].Lancet Oncol,2015,16(4):375-384.
[10] Robert C, Long G V, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation[J].N Engl J Med,2015,372(4):320-330.
[11] Herbst R S, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J].Lancet,2016,387(10027):1540-1550.
[12] Ribas A, Puzanov I, Dummer R,et al.Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial[J].Lancet Oncol, 2015,16(8):908-918.
[13] Tsalic M, Gilboa M, Visel B,et al. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity[J].Med Oncol,2006,23(1):57-61.
[14] Georgakopoulos C D, Makri O E, Vasilakis P, et al. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy[J].Clin Exp Optom, 2012,95(2):233-236.
[15] Coutzac C, Adam J, Soularue E, et al. Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities[J].J Crohns Colitis,2017,11(10):1238-1246.